Clinical trials: Neuromyelitis Optica
SLE, Sclerosis
A Study of RD06-04 in Patients With Active Autoimmune Diseases
This is an open-label, Phase I, investigator-initiated trial (IIT) aimed at evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of RD06-04 in patients with autoimmune diseases mediated by…
- Conditions
- SLE, Sclerosis, ANCA Associated Vasculitis, IIM
- Trial name
- NCT06548620
- Testing
- RD06-04 cell infusion
- Where
- China
- Sponsor
- Nanjing Bioheng Biotech Co., Ltd.
Neuromyelitis Optica Spectrum Disorder (NMOSD)
Efficacy and Safety of Low-Dose IL-2 in Neuromyelitis Optica Spectrum Disorder
Interleukin-2 (IL-2) is an essential cytokine for T-cell proliferation. Low-dose IL-2 has been shown to increase the proportion of regulatory T cells (Tregs), negatively regulate effector T cells such as Th17 and Tfh cells, and…
- Trial name
- NCT07809724
- Testing
- IL-2 (interleukin 2)
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Peking University People's Hospital
Neuromyelitis Optica
Autologous Hematopoietic Stem Cell Transplant in Neuromyelitis Optica
Neuromyelitis Optica (NMO) is a demyelinating and degenerative disorder of the CNS affecting vision and spinal cord function. This disease is rare compared to Multiple Sclerosis (MS), but it is devastating and often leads to…
- Trial name
- SCT-NMO (NCT01339455)
- Testing
- AHSCT
- Where
- Canada
- Volunteers
- 3 people
- Sponsor
- University of Calgary
Neuromyelitis Optica, Restless Legs Syndrome
Restless Legs Syndrome in People With Neuromyelitis Optica Spectrum Disorder
Restless legs syndrome (RLS) is a neurological movement disorder characterized by uncomfortable and uncontrollable sensations, usually in the legs, that increase at rest, and an urge to move the legs or other affected…
- Trial name
- NCT05573711
- Testing
- assessments
- Where
- Turkey (Türkiye)
- Volunteers
- 30 people
- Sponsor
- Dokuz Eylul University
Neuromyelitis Optica (NMO), Neuromyelitis Optica Spectrum Disorders (NMOSD)
Slow vs. Rapid Glucocorticoids Tapering With Inebilizumab in NMOSD
Neuromyelitis optica spectrum disorder (NMOSD) is a central nervous system autoimmune condition mainly involving the spinal cord, optic nerves, and area postrema.
- Trial name
- STARGlu-NMO (NCT07132398)
- Testing
- Slow-tapering glucocorticoids + Inebilizumab, Rapid-tapering glucocorticoids + Inebilizumab
- Volunteers
- 170 people
- Sponsor
- Tianjin Medical University General Hospital
Neuromyelitis Optica Spectrum Disorder
Long-term, Open-label, Safety Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD)
The purpose of this study is to understand the effects of long-term treatment with inebilizumab on circulating levels of immunoglobulins, B-cell counts, and other safety measures, and to further monitor repletion of immunoglobins…
- Trial name
- N-MOmentum LT (NCT06180278)
- Testing
- Blood tests, Inebilizumab
- Where
- 11 sites in United States, China and 5 more
- Volunteers
- 32 people
- Sponsor
- Amgen
Multiple Sclerosis, NMO Spectrum Disorder
A Study of LP-168 in Healthy Volunteers
This is a Phase I study designed to assess the safety, tolerability and pharmacokinetics of LP-168 in healthy human volunteers.
- Trial name
- NCT05432713
- Testing
- LP-168 tablet
- Where
- China
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Guangzhou Lupeng Pharmaceutical Company LTD.
Multiple Sclerosis, NMO Spectrum Disorder
Clinical Impact Through AI-assisted MS Care - A Retrospective Multi-center Observational Study.
The RECLAIM study aims to gather a centralized and harmonized dataset, enabling the secondary use of data for building AI-based models that will support diagnosis and prognosis of individual Multiple Sclerosis patient's disease…
- Conditions
- Multiple Sclerosis, NMO Spectrum Disorder, Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease, Radiologically Isolated Syndrome
- Trial name
- RECLAIM (NCT06280755)
- Where
- 3 sites in Czechia, Germany
- Volunteers
- 7,000 people, healthy volunteers welcome
- Sponsor
- icometrix
Neuromyelitis Optica Spectrum Disorders, Neuromyelitis Optica
Tocilizumab vs Azathioprine in Neuromyelitis Optica Spectrum Disorders
In neuromyelitis optica spectrum disorder (NMOSD),interleukin-6 (IL-6) may play an important role in facilitating plasma cells to produce pathological aquaporin 4 (AQP4) autoantibody.
- Trial name
- TANGO (NCT03350633)
- Testing
- Tocilizumab Injection, Azathioprine
- Where
- China
- Volunteers
- 118 people
- Sponsor
- Tianjin Medical University General Hospital
Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders
N-MOmentum: A Clinical Research Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorders
To compare the efficacy of inebilizumab (MEDI-551) versus placebo in reducing the risk of an neuromyelitis optica/neuromyelitis optica- spectrum disorders (NMO/NMOSD) attack in participants with NMO/NMOSD.
- Trial name
- NCT02200770
- Testing
- Inebilizumab
- Where
- 98 sites in United States, Australia and 23 more
- Volunteers
- 231 people
- Sponsor
- MedImmune LLC
Neuromyelitis Optica, Devic's Disease
Autologous Transplant To End NMO Spectrum Disorder
This study is designed to treat your disease with an autologous stem cell transplant using a regimen of immune suppressant drugs and chemotherapy to reset your immune system and to determine if your disease will go into long-term…
- Conditions
- Neuromyelitis Optica, Devic's Disease, NMO Spectrum Disorder
- Trial name
- ATTEND (NCT03829566)
- Testing
- Rituximab, Cyclophosphamide, Mesna
- Where
- 2 sites in United States
- Sponsor
- Northwestern University
NMO Spectrum Disorder, NMDA-R Encephalitis
Sensitivity and Specificity of TSA-CBA for Autoantibodies Against Neural Antigen Determination
Determination of autoantibodies against fragments derived from neurons, glia, and myelin sheath is instrumental in aiding diagnosis, differential diagnosis, as well as determining disease status of neuromyelitis optica spectrum…
- Conditions
- NMO Spectrum Disorder, NMDA-R Encephalitis, Diagnostic Self Evaluation, Immune System Diseases
- Trial name
- STAND (NCT05414890)
- Testing
- CBA-TSA
- Where
- China
- Volunteers
- 2,500 people, healthy volunteers welcome
- Sponsor
- Beijing Tiantan Hospital
Demyelinating Diseases of the Central Nervous System (DDC)
Demyelinating Diseases of the Central Nervous System Registry for Patients With Traditional Chinese Medicine (DATE-TCM)
Demyelinating Diseases of the Central Nervous System Registry for Patients with Traditional Chinese Medicine (DATE-TCM) is an observational study aiming to better define the multidimensional (epidemiologic, demographic and…
- Trial name
- NCT05415579
- Testing
- Traditional Chinese medicine (TCM)
- Volunteers
- 2,000 people
- Sponsor
- Dongzhimen Hospital, Beijing
NMO Spectrum Disorder;Registry Study
Clinic Registry Study of Optic Neuromyelitis Spectrum Disease in China
In 1894, Devic first proposed the concept of neuromyelitis optica(NMO). NMO is an inflammatory demyelinating disease that selectively affects the central nervous system of the optic nerve and spinal cord.In 2004, Lennon and other…
- Trial name
- NCT03514030
- Testing
- serum AQP4-antibody testing method
- Where
- China
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Beijing Tongren Hospital
Neuromyelitis Optica Spectrum Disorder, Transverse Myelitis
Central Pain Study for ABX-1431
This study will determine the safety and tolerability of ABX-1431 in patients with central pain when added on to background pain therapy.
- Conditions
- Neuromyelitis Optica Spectrum Disorder, Transverse Myelitis, Multiple Sclerosis, Longitudinally Extensive Transverse Myelitis
- Trial name
- NCT03138421
- Testing
- ABX-1431 HCl
- Where
- 2 sites in United Kingdom
- Volunteers
- 9 people
- Sponsor
- Abide Therapeutics
Neuromyelitis Optica Spectrum Disorders
A Study to Evaluate the Efficacy and Safety of JYP0061 in Patients With Acute Neuromyelitis Spectrum Disease (NMOSD)
The goal of this clinical trial is to evaluate the efficacy and safety, of JYP0061 in acute NMOSD patients. The main questions it aims to answer are: efficacy and safety of JYP0061 in acute NMOSD patients.
- Trial name
- NCT06697535
- Testing
- JYP0061, Intravenous Glucocorticoids, Oral Glucocorticoids
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Guangzhou JOYO Pharma Co., Ltd
Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorders
Efficacy and Safety of Mitoxantrone in Patients With Refractory Neuromyelitis Optica and Spectrum Disorders
The treatment protocol consisted of 12 mg/m2 MITO intravenous infusions every 3 months for 2 years. Dosage was adjusted according to side effects.
- Trial name
- NCT02021825
- Testing
- Mitoxantrone
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Xuanwu Hospital, Beijing
Neuromyelitis Optica Spectrum Disorders (NMOSD)
HANDLE-a Real World Study on Satralizumab in NMOSD
This study is a single-center, retrospective-prospective, non-interventional cohort study to assess the clinical outcomes of Chinese NMOSD patients treated with satralizumab in a real-world patient management model by collecting…
- Trial name
- NCT06829524
- Testing
- Satralizumab
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Huashan Hospital
Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder
Maintenance Plasma Exchange for Neuromyelitis Optica
Neuromyelitis optica (NMO) is an inflammatory disease of the central nervous system that is associated with autoantibodies to aquaporin-4.
- Conditions
- Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder, Recurrent Idiopathic Longitudinally Extensive Transverse Myelitis
- Trial name
- MultiPLEX (NCT01500681)
- Testing
- Plasma exchange (PLEX)
- Where
- 2 sites in United States
- Volunteers
- 9 people
- Sponsor
- Mayo Clinic
Optic Neuritis, Multiple Sclerosis
Early Prediction of Outcomes Following Optic Neuritis: Development and Acceptability of a Prognostic Tool
The goal of this observational study is to determine whether genetic information, together with clinical information, can be used to improve prediction of future multiple sclerosis (MS) diagnosis after a first-time episode of…
- Conditions
- Optic Neuritis, Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorder, Myelin Oligodendrocyte Glycoprotein (MOG)-Antibody Related Disorders
- Trial name
- MS Predictor (NCT07704294)
- Testing
- No Intervention: Observational Cohort
- Where
- 3 sites in United Kingdom
- Volunteers
- 180 people
- Sponsor
- King's College London